Patient Name : Mr.
RADHA GHANTASALA Collected : 26/Apr/2025 06:28AM
Age/Gender : 43 Y 8 M 4 D /M Received : 26/Apr/2025 10:28AM
UHID/MR No : APJ1.0028085868 Reported : 26/Apr/2025 11:35AM
Visit ID : DOENOPV12843 Status : Final Report
Ref Doctor : Dr. PRABHU Client Name : APOLLO 24X7
IP/OP NO : Center location : One Town,VIJAYAWADA
DEPARTMENT OF HAEMATOLOGY
APOLLO FULL BODY CHECKUP - ESSENTIAL
Test Name Result Unit Bio. Ref. Interval Method
COMPLETE BLOOD COUNT (CBC) , WHOLE BLOOD EDTA
HAEMOGLOBIN 15.2 g/dL 13-17 CYANIDE FREE
COLOUROMETER
PCV 41.80 % 40-50 PULSE HEIGHT AVERAGE
RBC COUNT 5.02 Million/cu.mm 4.5-5.5 Electrical Impedence
MCV 83.2 fL 83-101 Calculated
MCH 30.3 pg 27-32 Calculated
MCHC 36.4 g/dL 31.5-34.5 Calculated
R.D.W 15.3 % 11.6-14 Calculated
TOTAL LEUCOCYTE COUNT (TLC) 4,410 cells/cu.mm 4000-10000 Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DLC)
NEUTROPHILS 46 % 40-80 Electrical Impedance
LYMPHOCYTES 45 % 20-40 Electrical Impedance
EOSINOPHILS 04 % 1-6 Electrical Impedance
MONOCYTES 05 % 2-10 Electrical Impedance
BASOPHILS 00 % <1-2 Electrical Impedance
CORRECTED TLC 4,410 Cells/cu.mm Calculated
ABSOLUTE LEUCOCYTE COUNT
NEUTROPHILS 2028.6 Cells/cu.mm 2000-7000 Calculated
LYMPHOCYTES 1984.5 Cells/cu.mm 1000-3000 Calculated
EOSINOPHILS 176.4 Cells/cu.mm 20-500 Calculated
MONOCYTES 220.5 Cells/cu.mm 200-1000 Calculated
Neutrophil lymphocyte ratio (NLR) 1.02 0.78- 3.53 Calculated
PLATELET COUNT 151000 cells/cu.mm 150000-410000 IMPEDENCE/MICROSCOPY
MPV 10.2 Fl 8.1-13.9 Calculated
Page 1 of 7
SIN No:HA08859688
Patient Name : Mr.RADHA GHANTASALA Collected : 26/Apr/2025 06:28AM
Age/Gender : 43 Y 8 M 4 D /M Received : 26/Apr/2025 10:27AM
UHID/MR No : APJ1.0028085868 Reported : 26/Apr/2025 11:19AM
Visit ID : DOENOPV12843 Status : Final Report
Ref Doctor : Dr. PRABHU Client Name : APOLLO 24X7
IP/OP NO : Center location : One Town,VIJAYAWADA
DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ESSENTIAL
Test Name Result Unit Bio. Ref. Interval Method
GLUCOSE, FASTING , NAF PLASMA 123 mg/dL 70 - 100 GOD - POD
Comment:
As per American Diabetes Guidelines, 2023
Fasting Glucose Values in mg/dL Interpretation
70-100 mg/dL Normal
100-125 mg/dL Prediabetes
≥126 mg/dL Diabetes
<70 mg/dL Hypoglycemia
Note:
1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of
> or = 200 mg/dL on at least 2 occasions.
2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.
Page 2 of 7
SIN No:BI25452377
Patient Name : Mr.RADHA GHANTASALA Collected : 26/Apr/2025 06:28AM
Age/Gender : 43 Y 8 M 4 D /M Received : 26/Apr/2025 10:28AM
UHID/MR No : APJ1.0028085868 Reported : 26/Apr/2025 11:13AM
Visit ID : DOENOPV12843 Status : Final Report
Ref Doctor : Dr. PRABHU Client Name : APOLLO 24X7
IP/OP NO : Center location : One Town,VIJAYAWADA
DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ESSENTIAL
Test Name Result Unit Bio. Ref. Interval Method
HBA1C (GLYCATED HEMOGLOBIN) , WHOLE BLOOD EDTA
HBA1C, GLYCATED HEMOGLOBIN 5.3 % HPLC
ESTIMATED AVERAGE GLUCOSE 105 mg/dL Calculated
(eAG)
Comment:
Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:
REFERENCE GROUP HBA1C %
NON DIABETIC <5.7
PREDIABETES 5.7 – 6.4
DIABETES ≥ 6.5
DIABETICS
EXCELLENT CONTROL 6–7
FAIR TO GOOD CONTROL 7–8
UNSATISFACTORY CONTROL 8 – 10
POOR CONTROL >10
Note: Dietary preparation or fasting is not required.
1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic
Control by American Diabetes Association guidelines 2023.
2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is
advised in interpretation of low Values.
4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may
not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
A: HbF >25%
B: Homozygous Hemoglobinopathy.
(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)
Page 3 of 7
SIN No:BI25452378
Patient Name : Mr.RADHA GHANTASALA Collected : 26/Apr/2025 06:28AM
Age/Gender : 43 Y 8 M 4 D /M Received : 26/Apr/2025 10:28AM
UHID/MR No : APJ1.0028085868 Reported : 26/Apr/2025 11:34AM
Visit ID : DOENOPV12843 Status : Final Report
Ref Doctor : Dr. PRABHU Client Name : APOLLO 24X7
IP/OP NO : Center location : One Town,VIJAYAWADA
DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ESSENTIAL
Test Name Result Unit Bio. Ref. Interval Method
LIVER FUNCTION TEST (LFT) , SERUM
BILIRUBIN, TOTAL 0.70 mg/dL 0-1.2 DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT) 0.20 mg/dL 0.0-0.3 Calculated
BILIRUBIN (INDIRECT) 0.50 mg/dL 0-1.1 Dual Wavelength
ALANINE AMINOTRANSFERASE 57 U/L <50 Visible with P-5-P
(ALT/SGPT)
ASPARTATE AMINOTRANSFERASE 49.0 U/L 17-59 UV with P-5-P
(AST/SGOT)
AST (SGOT) / ALT (SGPT) RATIO (DE 0.9 <1.15 Calculated
RITIS)
ALKALINE PHOSPHATASE 54.00 U/L 38-126 p-nitrophenyl
phosphate
PROTEIN, TOTAL 7.50 g/dL 6.3-8.2 Biuret
ALBUMIN 4.80 g/dL 3.5 - 5 Bromocresol Green
GLOBULIN 2.70 g/dL 2.0-3.5 Calculated
A/G RATIO 1.78 0.9-2.0 Calculated
Comment:
LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of
bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:
1. Hepatocellular Injury: *AST – Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and
skeletal injuries.*ALT – Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for
hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with
ALP. AST: ALT (ratio) – In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This
ratio is also seen to be increased in NAFLD, Wilsons’s diseases, Cirrhosis, but the increase is usually not >2.Note- If both SGPT
and SGOT are within reference range then AST:ALT (De Ritis ratio) does not have any clinical significance.
2. Cholestatic Pattern:*ALP – Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in
pregnancy, impacted by age and sex.*Bilirubin (Direct) and GGT elevated- helps to establish hepatic origin.
3. Synthetic function impairment:*Albumin- Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
4. Associated tests for assessment of liver fibrosis - Fibrosis-4 and APRI Index.
Page 4 of 7
SIN No:BI25452376
Patient Name : Mr.RADHA GHANTASALA Collected : 26/Apr/2025 06:28AM
Age/Gender : 43 Y 8 M 4 D /M Received : 26/Apr/2025 10:28AM
UHID/MR No : APJ1.0028085868 Reported : 26/Apr/2025 11:34AM
Visit ID : DOENOPV12843 Status : Final Report
Ref Doctor : Dr. PRABHU Client Name : APOLLO 24X7
IP/OP NO : Center location : One Town,VIJAYAWADA
DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ESSENTIAL
Test Name Result Unit Bio. Ref. Interval Method
UREA. , SERUM 22.40 mg/dL 19-43 Urease
BLOOD UREA NITROGEN , SERUM 10.5 mg/dL 8.0 - 23.0 Calculated
Test Name Result Unit Bio. Ref. Interval Method
CALCIUM , SERUM 8.60 mg/dL 8.4 - 10.2 Arsenazo-III
Comments:-
Serum calcium measurements are done to monitor and diagnose disorders of skeletal system, parathyroid gland, kidney, muscular
disorders, and abnormal vitamin D and protein levels.
Test Name Result Unit Bio. Ref. Interval Method
CREATININE , SERUM 0.80 mg/dL 0.66-1.25 Creatinine
amidohydrolase
.eGFR - ESTIMATED GLOMERULAR 108.90 mL/min/1.73m² >60 CKD-EPI FORMULA
FILTRATION RATE , SERUM
Page 5 of 7
SIN No:BI25452376
Patient Name : Mr.RADHA GHANTASALA Collected : 26/Apr/2025 06:28AM
Age/Gender : 43 Y 8 M 4 D /M Received : 26/Apr/2025 10:28AM
UHID/MR No : APJ1.0028085868 Reported : 26/Apr/2025 11:34AM
Visit ID : DOENOPV12843 Status : Final Report
Ref Doctor : Dr. PRABHU Client Name : APOLLO 24X7
IP/OP NO : Center location : One Town,VIJAYAWADA
DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ESSENTIAL
Test Name Result Unit Bio. Ref. Interval Method
C-REACTIVE PROTEIN CRP 2.5 mg/L <10.0 IMMUNOENZYMATIC
(QUANTITATIVE) , SERUM
Comment:
C-reactive protein (CRP) is one of the most sensitive acute-phase reactants for inflammation. Measuring changes in the
concentration of CRP provides useful diagnostic information about the level of acuity and severity of a disease. Unlike ESR, CRP
levels are not influenced by hematologic conditions such as anemia, polycythemia etc.
Increased levels are consistent with an acute inflammatory process. After onset of an acute phase response, the serum CRP
concentration rises rapidly (within 6-12 hours and peaks at 24-48 hours) and extensively.Concentrations above 100 mg/L are
associated with severe stimuli such as major trauma and severe infection (sepsis).
Test Name Result Unit Bio. Ref. Interval Method
ELECTROLYTES - SERUM , SERUM
SODIUM 141 mmol/L 135-145 Direct ISE
POTASSIUM 3.5 mmol/L 3.5-5.1 Direct ISE
CHLORIDE 107 mmol/L 98 - 107 Direct ISE
Test Name Result Unit Bio. Ref. Interval Method
IRON , SERUM 103.0 µg/dL 49-181 Ferene
Comments:-
Iron exists in the body as haemoglobin in the circulating red cells, iron containing proteins such as myoglobin & cytochromes.
Serum, Iron levels are useful in the differential diagnosis of anemias, diagnosis of hemochromatosis & sideroblastic anemia. Iron
levels are useful in monitoring response to iron therapy.
Page 6 of 7
SIN No:BI25452376
Patient Name : Mr.RADHA GHANTASALA Collected : 26/Apr/2025 06:28AM
Age/Gender : 43 Y 8 M 4 D /M Received : 26/Apr/2025 10:28AM
UHID/MR No : APJ1.0028085868 Reported : 26/Apr/2025 11:34AM
Visit ID : DOENOPV12843 Status : Final Report
Ref Doctor : Dr. PRABHU Client Name : APOLLO 24X7
IP/OP NO : Center location : One Town,VIJAYAWADA
DEPARTMENT OF BIOCHEMISTRY
APOLLO FULL BODY CHECKUP - ESSENTIAL
Test Name Result Unit Bio. Ref. Interval Method
URIC ACID , SERUM 7.20 mg/dL 3.5-8.5 Uricase
Comments:-
Uric acid is an end product of purine catabolism. Most uric acid is synthesised in the liver & from the intestine.Two thirds of uric
acid is excreted by the kidneys.
*** End Of Report ***
Result/s to Follow:
VITAMIN B12, THYROID PROFILE TOTAL (T3, T4, TSH), ERYTHROCYTE SEDIMENTATION RATE (ESR), COMPLETE URINE EXAMINATION
(CUE), 25-HYDROXY VITAMIN D (D2+D3), LIPID PROFILE
Page 7 of 7
SIN No:BI25452376
Patient Name : Mr.RADHA GHANTASALA Collected : 26/Apr/2025 06:28AM
Age/Gender : 43 Y 8 M 4 D /M Received : 26/Apr/2025 10:28AM
UHID/MR No : APJ1.0028085868 Reported : 26/Apr/2025 11:34AM
Visit ID : DOENOPV12843 Status : Final Report
Ref Doctor : Dr. PRABHU Client Name : APOLLO 24X7
IP/OP NO : Center location : One Town,VIJAYAWADA
TERMS AND CONDITIONS GOVERNING THIS REPORT
1. Reported results are for information and interpretation of the referring doctor or such other medical professionals, who understand
reporting units, reference ranges and limitation of technologies. Laboratories not be responsible for any interpretation whatsoever
2. This is computer generated medical diagnostics report that has been validated by an Authorized Medical Practitioner/Doctor. The
report does not need physical signature.
3. Partial reproduction of this report is not valid and should not be resorted to draw any conclusion.
4. In the case you are not the intended recipient of this report. Please immediately return the same to the concerned issuing desk. Any
disclosure, copy or distribution of any contents of this report, is unlawful and is strictly prohibited.
5. Results delays may occur due to unforeseen circumstances such as non-availability of kits, equipment breakdown, natural calamities,
IT downtime, logistic delays or any other unavoidable event. For certain tests based on analyte stability, criticality of results and in the
interest of patient for having appropriate medical diagnosis, the same test may be outsourced to other accredited laboratory.
6. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of
particulars have been confirmed by the patient or his / her representative at the point of generation of said specimen
7. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same
parameter for the same patient (within subject biological variation).
8. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be
communicated to the assigned regulatory bodies
9. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of
the laboratory.
10. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only
SIN No:BI25452376
